Leukopenia
Conditions
Interventions
Medicine group:The subjects received a subcutaneous injection of 200 µg of human granulocyte colony-stimulating factor (JiLiFen, 50 µg, Hangzhou Jiuyuan Gene Engineering Co., Ltd.).
Control group:At the time of patient enrollment, health education was provided, informing the patients to strengthen protective measures, pay attention to environmental and personal hygiene, ensure ad
Moxibustion group:The subjects received continuous moxibustion treatment for 2 days. The specific method involved applying moxibustion with moxa sticks to the Zhongwan, Guanyuan, Dazhui, and bilateral
Sponsors
Beijing University of Chinese Medicine Third Affiliated Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Diagnosed with malignant tumors by histopathology or cytopathology; (2) Treatment regimen: chemotherapy implemented according to NCCN guidelines; may include targeted therapy or not. (3) Leukopenia occurring after chemotherapy with bone marrow suppression reaching Grade II (based on the WHO classification of acute and subacute toxic reactions to anticancer drugs): white blood cell count (2.0–2.9) × 10^9/L. (4) Aged between 18 and 75 years; (5) Performance status assessed by the Karnofsky Performance Scale (KPS) = 80; (6) Signed informed consent to voluntarily participate in this trial.
Exclusion criteria
Exclusion criteria: (1) Pregnant women or those intending to become pregnant as well as breastfeeding women; (2) Patients with severe hematological disorders autoimmune diseases or severe infections or chronic infectious diseases; (3) Those receiving other immune-related treatments such as PD-L1 inhibitors which may affect the evaluation of immune cell parameters; (4) Leukopenia or leukocytosis due to causes other than the treatment regimen such as splenomegaly or malignant tumor bone metastasis; (5) Individuals allergic to moxibustion or related medications; (6) Individuals with severe mental disorders; (7) Patients whose leukopenia exceeds Grade II after chemotherapy (i.e. reaching Grade III-IV).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood Routine; | — |
Secondary
| Measure | Time frame |
|---|---|
| lymphocyte subpopulation;TCR-seq; | — |
Countries
China
Contacts
Public ContactJinchang Huang
Beijing University of Chinese Medicine Third Affiliated Hospital
Outcome results
None listed